<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药智网 | wechat-feeds</title><link>http://MzAxODA5MTU3NQ.favicon.privacyhide.com/favicon.ico</link><description>让药物创造变得容易！我们致力于成为中国健康产业的传播者、服务者、推动者。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 05 Apr 2021 10:11:38 +0800</pubDate><image><url>http://MzAxODA5MTU3NQ.favicon.privacyhide.com/favicon.ico</url><title>药智网 | wechat-feeds</title><link>http://MzAxODA5MTU3NQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>市值260亿！他27岁弃医从商，创心脑血管龙头药企！</title><link>https://mp.weixin.qq.com/s/a-6eANswUWTEWU_Y3oPOuA</link><description></description><content:encoded><![CDATA[市值260亿！他27岁弃医从商，创心脑血管龙头药企！]]></content:encoded><pubDate>Mon, 05 Apr 2021 08:30:54 +0800</pubDate></item><item><title>【药咖君】两款License in新药获批上市！君实PD-1第3项适应症即将获批，基石药业、再鼎医药…</title><link>https://mp.weixin.qq.com/s/dxw43u3xI86oXwgIZzLvTA</link><description></description><content:encoded><![CDATA[【药咖君】两款License in新药获批上市！君实PD-1第3项适应症即将获批，基石药业、再鼎医药…]]></content:encoded><pubDate>Sun, 04 Apr 2021 10:06:07 +0800</pubDate></item><item><title>CDE药审分析，48个化药1类品种，59个一致性评价获受理，恒瑞、以岭药业…</title><link>https://mp.weixin.qq.com/s/NdKOkgJjB7_99wznTbxNZg</link><description></description><content:encoded><![CDATA[CDE药审分析，48个化药1类品种，59个一致性评价获受理，恒瑞、以岭药业…]]></content:encoded><pubDate>Fri, 02 Apr 2021 18:01:51 +0800</pubDate></item><item><title>52个品种过评，多款重磅注射剂!四川药企厉害了，科伦、成都倍特…</title><link>https://mp.weixin.qq.com/s/sIkgtPXijHKSCxUwOVbB-g</link><description></description><content:encoded><![CDATA[52个品种过评，多款重磅注射剂!四川药企厉害了，科伦、成都倍特…]]></content:encoded><pubDate>Fri, 02 Apr 2021 18:01:51 +0800</pubDate></item><item><title>市场萎缩483亿！集采带来行业内卷化，药企还活得下去吗？</title><link>https://mp.weixin.qq.com/s/CKtQnj_k2STifOi6_Ao18A</link><description></description><content:encoded><![CDATA[市场萎缩483亿！集采带来行业内卷化，药企还活得下去吗？]]></content:encoded><pubDate>Fri, 02 Apr 2021 11:39:35 +0800</pubDate></item><item><title>威凯尔医药第二代TRK抑制剂VC004项目完成关键剂量组爬坡试验</title><link>https://mp.weixin.qq.com/s/hCH9NWRQeEbr2tIE6VQn7A</link><description></description><content:encoded><![CDATA[威凯尔医药第二代TRK抑制剂VC004项目完成关键剂量组爬坡试验]]></content:encoded><pubDate>Fri, 02 Apr 2021 11:39:35 +0800</pubDate></item><item><title>一文盘点肿瘤免疫治疗不良反应与新靶点！</title><link>https://mp.weixin.qq.com/s/gxpP-j_HUUGoPQjCBbGFlw</link><description></description><content:encoded><![CDATA[一文盘点肿瘤免疫治疗不良反应与新靶点！]]></content:encoded><pubDate>Fri, 02 Apr 2021 11:39:35 +0800</pubDate></item><item><title>最新！31家药企高管离职（附名单）</title><link>https://mp.weixin.qq.com/s/foy11Te1b1BjOBb1kP-dKQ</link><description></description><content:encoded><![CDATA[最新！31家药企高管离职（附名单）]]></content:encoded><pubDate>Fri, 02 Apr 2021 11:39:35 +0800</pubDate></item><item><title>制药企业营收Top榜出炉！强生夺冠，辉瑞下跌至第八，安斯泰来新上榜...</title><link>https://mp.weixin.qq.com/s/N6bHuA6bVytGg1iOPLtXJw</link><description></description><content:encoded><![CDATA[制药企业营收Top榜出炉！强生夺冠，辉瑞下跌至第八，安斯泰来新上榜...]]></content:encoded><pubDate>Thu, 01 Apr 2021 18:09:17 +0800</pubDate></item><item><title>ADC药物崭露头角？齐鲁、石药、恒瑞...</title><link>https://mp.weixin.qq.com/s/zCAS7KplZjjSOg-YCE738w</link><description></description><content:encoded><![CDATA[ADC药物崭露头角？齐鲁、石药、恒瑞...]]></content:encoded><pubDate>Thu, 01 Apr 2021 18:09:17 +0800</pubDate></item><item><title>用量大都会进集采吗？漏洞已补上：不参与、串标、风险防范</title><link>https://mp.weixin.qq.com/s/vejRAh1YdVqJL66kM0MekQ</link><description></description><content:encoded><![CDATA[用量大都会进集采吗？漏洞已补上：不参与、串标、风险防范]]></content:encoded><pubDate>Thu, 01 Apr 2021 18:09:17 +0800</pubDate></item><item><title>多家药企补贴曝光，哪个才是真正的好企业？</title><link>https://mp.weixin.qq.com/s/5xs65k2Jon9LYukMK6I2eA</link><description></description><content:encoded><![CDATA[多家药企补贴曝光，哪个才是真正的好企业？]]></content:encoded><pubDate>Thu, 01 Apr 2021 18:09:17 +0800</pubDate></item><item><title>总融资额超180亿，总估值近2000亿，一季度医药行业所有融资中均与创新药相关？</title><link>https://mp.weixin.qq.com/s/Hkw4ehWtiF1TVkkGqI1pGw</link><description></description><content:encoded><![CDATA[总融资额超180亿，总估值近2000亿，一季度医药行业所有融资中均与创新药相关？]]></content:encoded><pubDate>Wed, 31 Mar 2021 18:22:19 +0800</pubDate></item><item><title>重磅，新冠疫苗第二针推迟一周后再打</title><link>https://mp.weixin.qq.com/s/3bmbFtQ1WS_9SQt7zQ3HuA</link><description></description><content:encoded><![CDATA[重磅，新冠疫苗第二针推迟一周后再打]]></content:encoded><pubDate>Wed, 31 Mar 2021 18:22:19 +0800</pubDate></item><item><title>知名药企宣布，裁撤员工</title><link>https://mp.weixin.qq.com/s/9xdE4Nyb1K6dvrN_DyaaqA</link><description></description><content:encoded><![CDATA[知名药企宣布，裁撤员工]]></content:encoded><pubDate>Wed, 31 Mar 2021 18:22:19 +0800</pubDate></item><item><title>重磅！69个药品被医保盯上了</title><link>https://mp.weixin.qq.com/s/h1_pPmfxZUUJnKh74rclCQ</link><description></description><content:encoded><![CDATA[重磅！69个药品被医保盯上了]]></content:encoded><pubDate>Wed, 31 Mar 2021 18:22:19 +0800</pubDate></item><item><title>2021太湖湾生命健康未来大会</title><link>https://mp.weixin.qq.com/s/9VJTNG9b7fXB1asvHtPE1w</link><description></description><content:encoded><![CDATA[2021太湖湾生命健康未来大会]]></content:encoded><pubDate>Wed, 31 Mar 2021 18:22:19 +0800</pubDate></item><item><title>CXO龙头康龙化成2020年业绩强劲依旧，临床研究服务增速最高</title><link>https://mp.weixin.qq.com/s/PppsqvqCLUSeSU7O48glvQ</link><description></description><content:encoded><![CDATA[CXO龙头康龙化成2020年业绩强劲依旧，临床研究服务增速最高]]></content:encoded><pubDate>Tue, 30 Mar 2021 15:08:44 +0800</pubDate></item><item><title>生物医药创新“百花齐放”，临床研发快车道在哪里？</title><link>https://mp.weixin.qq.com/s/7HV5ekAdx_vXBNR_ahIvLw</link><description></description><content:encoded><![CDATA[生物医药创新“百花齐放”，临床研发快车道在哪里？]]></content:encoded><pubDate>Tue, 30 Mar 2021 15:08:44 +0800</pubDate></item><item><title>在第五批集采前，这些省已经开始集采了</title><link>https://mp.weixin.qq.com/s/DtntUEPHFaayuXqxSpCo9g</link><description></description><content:encoded><![CDATA[在第五批集采前，这些省已经开始集采了]]></content:encoded><pubDate>Tue, 30 Mar 2021 15:08:44 +0800</pubDate></item></channel></rss>